WO2017190345A1 - Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging - Google Patents

Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging Download PDF

Info

Publication number
WO2017190345A1
WO2017190345A1 PCT/CN2016/081265 CN2016081265W WO2017190345A1 WO 2017190345 A1 WO2017190345 A1 WO 2017190345A1 CN 2016081265 W CN2016081265 W CN 2016081265W WO 2017190345 A1 WO2017190345 A1 WO 2017190345A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
independently
unit
mmol
shielding
Prior art date
Application number
PCT/CN2016/081265
Other languages
English (en)
French (fr)
Inventor
Yongye Liang
Huasen WANG
Qinglai YANG
Meijie TANG
Su Zhao
Original Assignee
South University Of Science And Technology Of China
Nirmidas Biotech, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by South University Of Science And Technology Of China, Nirmidas Biotech, Inc. filed Critical South University Of Science And Technology Of China
Priority to PCT/CN2016/081265 priority Critical patent/WO2017190345A1/en
Priority to CN201680087445.5A priority patent/CN109641921B/zh
Publication of WO2017190345A1 publication Critical patent/WO2017190345A1/en

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains two hetero rings
    • C07D517/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • Organic molecules dyes could be a better alternative as they can be made to be more biocompatible and easily excreted from the body than inorganic nanomaterials.
  • Molecular fluorophore properties could be easily tuned by structure engineering.
  • the general molecular fluorescent agents such as indocyanine green (ICG) , methylene blue (MB) and fluorescein isothiocyanate (FITC)
  • ICG indocyanine green
  • MB methylene blue
  • FITC fluorescein isothiocyanate
  • Some polymethine dyes, such as IR-26, IR-1051 and IR-1100 could have emission in the SWIR region. But these dyes have never been used for biological imaging as none of them is water-soluble.
  • SWIR fluorophores Although small molecule dye and polymers have been used as SWIR fluorophores, they have to be encapsulated in a hydrophilic polymer matrix because of their low solubility in aqueous solution. Such encapsulation significantly increases the particle size, prevents rapid excretion and lowers the quantum yield. Recently, a molecular dye CH1055 has been reported with SWIR emission and demonstrated renal excretion. However, the emission quantum yield of such dye is too low (less than 0.2%) for real-time imaging, the size (molecular weight 9.7 k Da) is relatively large and the fluorescence is limited below ⁇ 1200 nm.
  • SWIR fluorophores with good aqueous solubility and biocompatibility, high quantum yield, fluorescence emission at longer wavelength than previously reported and highly efficient conjugation to biological molecules, which is of vital importance to fully develop SWIR fluorescence-based imaging methods for research and potential clinical translation.
  • This invention comprises design, synthesis and application of molecular fluorophores for bioimaging in the SWIR or SWIR window. Some molecular fluorophores can be extended to NIR window. Embodiments of the present disclosure seek to solve at least one of the problems existing in the related art to at least some extent, which include: 1) low emission quantum yield. 2) limited solubility of molecular fluorophores in aqueous and biological solutions. 3) low efficiency of conjugation to biological molecules including targeting ligands or antibodies. 4) the fluorescence is limited below ⁇ 1200 nm. In the present invention, a donor-acceptor-donor structure and a strong acceptor unit are employed to afford low band gap of the molecular fluorophores.
  • SWIR fluorophores with fluorescence > 1200nm, which is superior to the CH1055 dye with fluorescence ⁇ 1200nm and can afford much reduced scattering effects in vivo and thus deeper tissue imaging depth.
  • SWIR dyes also contain azide groups to facilitate bio-conjugation with ultrahigh efficiency superior to N-hydroxysuccinimide (NHS) esters based conjugation.
  • Embodiments of a first broad aspect of the present disclosure provide a compound, comprising:
  • a shielding unit shielding the electron accepting aromatic unit and/or the electron donating aromatic unit from intermolecular interactions
  • n1 is an integer ranging from 1 to 12.
  • each R 1 is independently H, C n2 H 2n2+1 , or tert-butyloxycarbonyl,
  • each one of Y 1 and Y 2 is independently H, OC n2 H 2n2+1 , C n2 H 2n2+1 , OC n2 H 2n2 B, or C n2 H 2n2 Z,
  • each B is independently Br, I, OTs, OMs, ONs, N3, or OMe,
  • each Z is independently Br, or N3,
  • each n2 is independently an integer ranging from 1 to 20,
  • each p is independently an integer ranging from 1 to 20,
  • the shielding unit has a formula of any one selected from the group consisting of:
  • each R 2 is independently OC n3 H 2n3+1 , C n3 H 2n3+1 , OC n3 H 2n3 W, or C n3 H 2n3 W,
  • each n3 is independently an integer ranging from 0 to 20,
  • each W is independently H, Br, I, OH, OTs, N 3 ,
  • each X 1 is independently Si, Ge, or C,
  • n5 is an integer ranging from 1 to 20,
  • n is an integer ranging from 4 to 120
  • the compound comprises two shielding units and two electron donating aromatic units, and the compound has a formula of : S’1-D1-A-D2-S’2, wherein
  • S’1 represents a first shielding unit
  • D1 represents a first electron donating aromatic unit
  • D2 represents a second electron donating aromatic unit
  • A represents the electron accepting aromatic unit.
  • the compound has a formula of: S’-D-A, wherein
  • the compound comprises two electron accepting aromatic units, three electron donating aromatic units, and two shielding units, and the compound has a formula of : S’3-D3-A1-D5-A2-D4-S’4, wherein
  • S’3 represents a third shielding unit
  • S’4 represents a forth shielding unit
  • D3 represents a third electron donating aromatic unit
  • D4 represents a forth electron donating aromatic unit
  • D5 represents a forth electron donating aromatic unit
  • A1 represents a first electron accepting aromatic unit
  • A2 represents a second electron accepting aromatic unit.
  • the compound comprises one electron accepting aromatic unit, two shielding units, and the compound has a formula of : S’5-A-S’6, wherein
  • S’6 represents a sixth shielding unit
  • A represents the electron accepting aromatic unit.
  • the compound comprises one electron accepting aromatic unit, four shielding units, and the compound has a formula of : S’7-S’8-A-S’9-S’10, wherein
  • S’7 represents a seventh shielding unit
  • S’8 represents an eighth shielding unit
  • S’9 represents a ninth shielding unit
  • S’10 represents a tenth shielding unit
  • the compound having a formula of any one selected from the group consisting of:
  • each one of Y 1 and Y 2 is independently H, C n2 H 2n2+1 , OC n2 H 2n2+1 , OC n2 H 2n2 B,
  • the compound having a formula of any one selected from the group consisting of:
  • Embodiments of a third broad aspect of the present disclosure provide use of the compound or the kit mentioned above in labeling or conjugating to a biomolecule.
  • the biomolecule and the compound mentioned above are combined together through click chemistry with azide groups on the compound mentioned above or intermolecular forces to form strong, non-covalent complexes through simple mixing or mixing followed by heating to 40-70 degree Celsius.
  • the biomolecule includes a small bioactive molecule (folic acid, tretinoin, cholic acid, galactose, biotin, etc. ) , a peptide (decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • a small bioactive molecule folic acid, tretinoin, cholic acid, galactose, biotin, etc.
  • a peptide decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • an antibody (erbitux, anti-SA2, Herceptin, secondary antibody against human or animal antibodies, abciximab, adalimumab, alemtuzumab, basiliximab, belimumab, bevacizumab, brentuximab vedotin, canakinumab, cetuximab, certolizumab pegol, daclizumab, daratumumab, denosumab, eculizumab, efalizumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, nivolumab, ofatumumab, omalizumab, palivizumab, panitumumab, Pembrolizumab, ranibizumab, rituximab, tocilizumab,
  • Embodiments of a forth broad aspect of the present disclosure provide a conjugate of the compound mentioned above to a biomolecule, wherein the biomolecule comprising a small bioactive molecule, a peptide, an antibody, a protein, an affibody, a nucleic acid, and an aptamer modified with terminal alkynyl.
  • the biomolecule and the compound mentioned above are conjugated together through click chemistry with azide groups on the compound mentioned above or intermolecular forces to form strong, non-covalent complexes through simple mixing or mixing followed by heating to 40-70 degree Celsius.
  • the biomolecule described here is the same with the biomolecule mentioned above, and will not be described in detail again.
  • the biomolecule described here is the same with the biomolecule mentioned above, and will not be described in detail again.
  • Embodiments of a sixth broad aspect of the present disclosure provide a method of biomedical imaging, comprising:
  • the subject comprising an animal, a human, a tissue, a cell, a 3D organoid or a spheroid.
  • the compound, the kit or the conjugate mentioned above are administrated into a blood vessel, a tissue, an organ, or a lymph node of the subject.
  • the NIR light source is a laser light source or a light emitting diode, and the wavelength of the NIR light source is 780nm, 808nm, or 980 nm.
  • imaging blood vessels with fluorophore circulation in brain, eye or other organs of a body of human or animals sentinel lymph node (SLN) mapping to image lymph nodes proximal to tumor for diagnosis of cancer metastasis, or molecular imaging of cancer though fluorophore-biomolecule targeted homing to cancer cells in the body.
  • SSN sentinel lymph node
  • Embodiments of a seventh broad aspect of the present disclosure provide a method of imaging guided tumor surgery, comprising:
  • Embodiments of an eighth broad aspect of the present disclosure provide a method for labeling a biomolecule, comprising:
  • the biomolecule includes a small bioactive molecule (folic acid, tretinoin, cholic acid, galactose, biotin, etc. ) , a peptide (decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • a small bioactive molecule folic acid, tretinoin, cholic acid, galactose, biotin, etc.
  • a peptide decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • biomolecule is used in combination of an SWIR dye as described here that is linked to a molecule or molecular fragment that specifically binds to a marker of interest in a target.
  • SWIR dye as described here that is linked to a molecule or molecular fragment that specifically binds to a marker of interest in a target.
  • Some specific peptide receptors were also displayed the highest binding affinity and specificity with their “peptides” ligands by their ligand receptor, which can directionally deliver peptides-dye conjugation ligands to targeted cell and tissue.
  • Antibody molecule is any immunoglobulin, including antibodies and fragments, its binds to a specific antigen, which can contemplate recombinant generated intact immunoglobulin molecules and immunologically active portions of an immunoglobulin molecule.
  • the targeted bio-imaging or molecular imaging can be achieved in vivo, in vitro or ex vivo.
  • the compounds mentioned above in the present invention can be used as molecular SWIR fluorophores with enhanced quantum yield and good biocompatibility. These compounds exhibit fluorescence in the range from 900-1700 nm under the excitation of light in the range of 400-1000 nm, the intermolecular and intramolecular interactions of the conjugated backbone are reduced and the quantum yield is enhanced. Meanwhile, the molecular fluorophores (the compounds mentioned above) exhibit good water solubility and the dynamic range of the dyes in aqueous solution is small enough to ensure rapid urine or fecal excretion through the renal or biliary system and little toxicity. The high quantum yield and biocompatibility of the molecular dyes along with their SWIR emission opens up the opportunities of SWIR imaging using molecular fluorophores for in-vivo applications.
  • any embodiment disclosed herein can be combined with other embodiments as long as they are not contradictory to one another, even though the embodiments are described under different aspects of the invention.
  • any technical feature in one embodiment can be applied to the corresponding technical feature in other embodiments as long as they are not contradictory to one another, even though the embodiments are described under different aspects of the invention.
  • Fig 2 shows SWIR imaging of a mouse’s brain blood vessels with the IRETBN-PEG1700 fluorophore circulating in the blood flow of the mouse through tail vein injection.
  • Fig 3 shows SWIR fluorescence images of a 4T1 tumor bearing mouse after injection of IREFNS solution.
  • the fluorophores accumulate in the tumor through EPR effect, allowing for tumor imaging with high tumor/normal tissue signal ratio.
  • Fig 4 shows a schematic of conjugation between alkyne functional biomolecules and the azide functionalized SWIR fluorophore.
  • Fig 5 shows fluorescence of samples after density gradient ultra-centrifugation (DGU) separation of fluorophore-protein conjugate and free fluorophore excited by an 808 nm laser.
  • DGU density gradient ultra-centrifugation
  • grammatical articles “a” , “an” and “the” are intended to include “at least one” or “one or more” unless otherwise indicated herein or clearly contradicted by the context.
  • the articles are used herein to refer to one or more than one (i.e. at least one) of the grammatical objects of the article.
  • a component means one or more components, and thus, possibly, more than one component is contemplated and may be employed or used in an implementation of the described embodiments.
  • Embodiments of a first broad aspect of the present disclosure provide a compound, comprising:
  • a shielding unit shielding the electron accepting aromatic unit and/or the electron donating aromatic unit from intermolecular interactions
  • each one of Z 1 , and Z 2 is independently O, S, Se, or NR,
  • each R is independently H, C 2n+1 H 2n+1 , or tert-butyloxycarbonyl,
  • n1 is an integer ranging from 1 to 12.
  • the electron donating aromatic unit has a formula of any one selected from the group consisting of:
  • each X is independently S, Se, NR 1 , or O,
  • each B is independently Br, I, OTs, OMs, ONs, N3, or OMe,
  • each m is independently an integer ranging from 0 to 6
  • each n2 is independently an integer ranging from 1 to 20,
  • each p is independently an integer ranging from 1 to 20.
  • substitution of the “D” unit (the electron donating aromatic unit) close to the “A” unit (the electron accepting aromatic unit) side is preferred, which can improve the quantum yield of molecular dyes in aqueous solution, possibly due to the reduced intermolecular and intramolecular interactions.
  • substitution of the “D” unit (the electron donating aromatic unit) close to the “A” unit (the electron accepting aromatic unit) side is preferred, which can improve the quantum yield of molecular dyes in aqueous solution, possibly due to the reduced intermolecular and intramolecular interactions.
  • the shielding unit has a formula of any one selected from the group consisting of:
  • each R 2 is independently OC n3 H 2n3+1 , C n3 H 2n3+1 , OC n3 H 2n3 W, or C n3 H 2n3 W,
  • each n3 is independently an integer ranging from 0 to 20,
  • each p1 is independently an integer ranging from 1 to 20,
  • each one of Z 5 , Z 6 , and Z 7 is independently S, Se, O, or NR 2 ’,
  • R 2 ’ is H, C n5 H 2n5+1 , or tert-butyloxycarbonyl
  • each X 1 is independently Si, Ge, or C,
  • each b is independently an integer ranging from 1 to 6.
  • the shielding unit contains side chains extended out of the plane of conjugated backbone (the electron accepting aromatic unit and/or the electron donating aromatic unit) , which can reduce the stacking of the molecular conjugated backbone.
  • the terminals of the side chains are functionalized with polyethylene glycol (PEG) , ionic group (such as quaternary ammonium salt) , which can enhance aqueous solubility.
  • PEG polyethylene glycol
  • ionic group such as quaternary ammonium salt
  • the terminals of the side chains are functionalized with azide group (N3) for further conjugation with targeting ligands.
  • the compound comprises two shielding units and two electron donating aromatic units
  • the compound has a formula of : S’1-D1-A-D2-S’2, wherein S’1 represents a first shielding unit, S’2 represents a second shielding unit, D1 represents a first electron donating aromatic unit, D2 represents a second electron donating aromatic unit, A represents the electron accepting aromatic unit.
  • S’1 represents one shielding unit of the two shielding units
  • S’2 represents the other shielding unit of the two shielding units
  • D1 represents one electron donating aromatic unit of the two electron donating aromatic units
  • D2 represents the other electron donating aromatic unit of the two electron donating aromatic units.
  • the compound has a formula of: S’-D-A, wherein S’represents the shielding unit, D represents the electron donating aromatic unit, A represents the electron accepting aromatic unit.
  • the compound comprises two electron accepting aromatic units, three electron donating aromatic units, and two shielding units, and the compound has a formula of : S’3-D3-A1-D5-A2-D4-S’4, wherein S’3 represents a third shielding unit, S’4 represents a forth shielding unit, D3 represents a third electron donating aromatic unit, D4 represents a forth electron donating aromatic unit, D5 represents a fifth electron donating aromatic unit, A1 represents a first electron accepting aromatic unit, A2 represents a second electron accepting aromatic unit.
  • S’3 represents one shielding unit of the two shielding units
  • S’4 represents the other shielding unit of the two shielding units.
  • the compound comprises one electron accepting aromatic unit, two shielding units, and the compound has a formula of : S’5-A-S’6, wherein
  • S’6 represents a sixth shielding unit
  • A represents the electron accepting aromatic unit.
  • the compound having a formula of any one selected from the group consisting of:
  • each one of Y 1 and Y 2 is independently H, C n2 H 2n2+1 , OC n2 H 2n2+1 , OC n2 H 2n2 B,
  • the compound having a formula of any one selected from the group consisting of:
  • -PEG600 represents the formula of 600, 700, and 1000 represent the weight average molecular weight, and the value of n depends on the weight average molecular weight.
  • the biomolecule and the compound mentioned above are combined together through click chemistry with azide groups on the compound mentioned above or intermolecular forces to form strong, non-covalent complexes through simple mixing or mixing followed by heating to 40-70 degree Celsius.
  • the biomolecule includes a small bioactive molecule (folic acid, tretinoin, cholic acid, galactose, biotin, etc. ) , a peptide (decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • a small bioactive molecule folic acid, tretinoin, cholic acid, galactose, biotin, etc.
  • a peptide decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • a protein streptavidin, etc.
  • an affibody a nucleic acid, and an aptamer, which are modified with terminal alkynyl and then click reacted with fluorophores’azide.
  • Embodiments of a forth broad aspect of the present disclosure provide a conjugate of the compound mentioned above to a biomolecule, wherein the biomolecule comprising a small bioactive molecule, a peptide, an antibody, a protein, an affibody, a nucleic acid, and an aptamer modified with terminal alkynyl.
  • the conjugate can be used as molecular fluorescence for biomedical imaging, such as blood vessel imaging (brain vessel for TBI, tumor vessel) , tumor imaging and so on.
  • the biomolecule and the compound mentioned above are conjugated together through click chemistry with azide groups on the compound mentioned above or intermolecular forces to form strong, non-covalent complexes through simple mixing or mixing followed by heating to 40-70 degree Celsius.
  • the biomolecule described here is the same with the biomolecule mentioned above, and will not be described in detail again.
  • Embodiments of a fifth broad aspect of the present disclosure provide use of the compound, the kit, or the conjugate mentioned above in biomedical imaging.
  • the compound, or the kit, or the conjugate mentioned above can be used as molecular fluorescence for biomedical imaging with enhanced quantum yield and good biocompatibility.
  • the biomolecule described here is the same with the biomolecule mentioned above, and will not be described in detail again.
  • Embodiments of a sixth broad aspect of the present disclosure provide a method of biomedical imaging, comprising: administrating the compound, the kit or the conjugate to a subject, irradiating the subject at a site of interest by NIR light source, and recording an image by a camera.
  • the quantum yield and biocompatibility are improved significantly by using the compound or the conjugate mentioned above as molecular fluorescence.
  • the site of interest comprising vessels (brain vessels, tumor vessels, etc. ) , tumor, lymphatic system, and so on.
  • the subject comprising an animal, a human, a tissue, a cell, a 3D organoid or a spheroid.
  • the method of the present invention can be effectively used for non-invasive biomedical imaging of animal or human body, such as targeted tumor imaging, vascular imaging, lymph system imaging, and other targets in various parts of the animal or human body, which can be used for clinical diagnosis.
  • the compound or the conjugate mentioned above are administrated into a blood vessel, a tissue, an organ or a lymph node of the subject.
  • the compound or the conjugate are able to accumulate in the target area, then the image of the target area can be obtained easily.
  • the camera comprising an InGaAs camera for imaging in 900nm-1700nm, a Si charge coupled device (CCD) or camera with or without NIR enhanced detector for imaging in 800-1100nm range.
  • CCD Si charge coupled device
  • imaging blood vessels with fluorophore circulation in brain, eye or other organs of a body of human or animals sentinel lymph node (SLN) mapping to image lymph nodes proximal to tumor for diagnosis of cancer metastasis, or molecular imaging of cancer though fluorophore-biomolecule targeted homing to cancer cells in the body.
  • SSN sentinel lymph node
  • Embodiments of a seventh broad aspect of the present disclosure provide a method of imaging guided tumor surgery, comprising: recording an image of the targeted area by method of biomedical imaging mentioned above, using the image to guide tumor removal.
  • the method of the present invention can reduce tumor surgery difficulty, and improve the accuracy of the operation.
  • Embodiments of an eighth broad aspect of the present disclosure provide a method for labeling a biomolecule, comprising: making the compound or the kit mentioned above reacting with the biomolecule, or mixing the compound or the kit mentioned above with the biomolecule with or without heating to 40-70 degree Celsius.
  • the biocompatibility and fluorescence intensity are improved significantly by using the compound mentioned above as molecular fluorescence.
  • the biomolecule includes a small bioactive molecule (folic acid, tretinoin, cholic acid, galactose, biotin, etc. ) , a peptide (decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • a small bioactive molecule folic acid, tretinoin, cholic acid, galactose, biotin, etc.
  • a peptide decapeptide: synB3, ovarian cancer specific binding peptide: OSBP-1 and OSBP-S, etc.
  • an affibody an antibody (erbitux, anti-SA2, Herceptin, secondary antibody against human or animal antibodies, abciximab, adalimumab, alemtuzumab, basiliximab, belimumab, bevacizumab, brentuximab vedotin, canakinumab, cetuximab, certolizumab pegol, daclizumab, daratumumab, denosumab, eculizumab, efalizumab, golimumab, ibritumomab tiuxetan, infliximab, ipilimumab, muromonab-CD3, natalizumab, nivolumab, ofatumumab, omalizumab, palivizumab, panitumumab, Pembrolizumab, ranibizumab, rituximab,
  • the compounds mentioned above in the present invention can be used as molecular SWIR fluorophores with enhanced quantum yield and good biocompatibility. These compounds exhibit fluorescence in the range from 900-1700 nm under the excitation of light in the range of 400-1000 nm, the intermolecular and intramolecular interactions of the conjugated backbone are reduced and the quantum yield is enhanced. Meanwhile, the molecular fluorophores (the compounds mentioned above) exhibit good water solubility and the dynamic range of the dyes in aqueous solution is small enough to ensure rapid urine or fecal excretion through the renal or biliary system and little toxicity. The high quantum yield and biocompatibility of the molecular dyes along with their SWIR emission opens up the opportunities of SWIR imaging using molecular fluorophores for in-vivo applications.
  • Example 2 Synthesis of IREF-PEG600 and IREFN-PEG600.
  • IREF-PEG600 (250 mg) was afforded as a green oil.
  • MALDI-TOF-MS expected M.W. about 3,700, measured M.W. 3,700.
  • IREFN-PEG600 was prepared as green oil with the same method by changing the amount of HO-PEG-Alkyne-0.6k to 85 mg.
  • MALDI-TOF-MS expected M.W. about 2,800, measured weight average M.W. about 2,800.
  • MALDI-TOF-MS expected M.W. about 5,208, measured M.W. 5,210. And IRDTN-PEG1000 was afforded as green oil with the same method but changing the amount of w-alkynyl-PEG-hydroxyl to 85 mg.
  • MALDI-TOF-MS expected M.W. about 3,198, measured weight average M.W. about 3,200.
  • UV-Vis-NIR spectrophotometer (UV 3600) with background correction was employed to measure the optical absorption spectra in water in the range of 300-1,200 nm.
  • a home build setup was used to measure the fluorescence spectrum of IR-E1 in the region of 900-1,600 nm using an array detector (Princeton OMA-V) and a spectrometer (Acton SP2300i) under an 808-nm diode laser (RMPC lasers) excitation (160 mW) .
  • RMPC lasers 808-nm diode laser
  • emission filters an 850-nm (Thorlabs) , 1,000-nm (Thorlabs) , 1,100-nm (Omega) and 1,300-nm short-pass filter (Omega) were used as excitation filters and 900-nm long-pass filter (Thorlabs) was used as emission filter.
  • the obtained emission spectra were further corrected by the detector sensitivity profile and the absorbance features of the filter.
  • Fig 1a Absorption and emission spectra of IRETBN-PEG1700 in aqueous solution were shown in Fig 1a, fluorescence intensity of IRETBN-PEG1700 in water and PBS measured over 1 week were shown in Fig 1b.
  • IRETBN-PEG1700 In aqueous solution, IRETBN-PEG1700 exhibited an absorption peak at 830 nm, while the fluorescence emission spectrum showed emission range from 1000 to 1400 nm with a main emission peak at around 1080 nm (Fig. 1a) .
  • the weight average molecular weight (MW) of IRETBN-PEG1700 was ⁇ 4.5 kDa with a hydrodynamic size of ⁇ 3.6 nm in aqueous solution.
  • the commercial SWIR fluorescent IR-26 dye was used as the reference sample with the quantum yield of 0.5%.
  • the IR-26 was dissolved in 1, 2-dichloroethane (DCE) , and diluted to different concentration with absorbance value at 808 nm of ⁇ 0.067, ⁇ 0.029, ⁇ 0.014 and ⁇ 0.002 using a ultraviolet-visible-near-infrared absorbance spectrometer.
  • the fluorescence spectra in the range of 900-to 1,600-nm was collected (900-nm long-pass filter) under the 808-nm diode laser (RMPC lasers) excitation.
  • the absorption and emission of compounds of examples 1 to 6 in water were measured using same method with IR-26.
  • QY stands for quantum yields
  • n refractive index of the solvent
  • A absorbance of the solution
  • I fluorescence intensity
  • Example 16 Non-invasive SWIR fluorescence imaging for brain blood vessels
  • the PBS solution of IRETBN-PEG1700 (1 mg/ml, 200 ⁇ L) was injected into hair removed mouse for SWIR imaging.
  • An 808 nm laser was used as excitation (140 mW ⁇ cm -2 ) filtered through 850 nm short-pass filter.
  • Dynamic imaging was done with a 2D InGaAs camera (Princeton Instrument 2D-OMA V: 320) with exposure time of 300 ms in the > 1300 nm range (by collecting emission through 1, 300-nm long-pass filter) .
  • SWIR fluorescence signals in the inferior cerebral vein, transverse sinus and middle cerebral vessels in the contralateral hemisphere showed up immediately within 1 s post injection, and these signals rapidly increased and plateaued at ⁇ 10 s (Figure 2) .
  • SWIR imaging of a mouse’s brain blood vessels with the IRETBN-PEG1700 fluorophore were shown in Figure 2.
  • the PBS solution of IREFNS (0.3 mg/ml, 350 ⁇ L) was injected intravenously into a mouse with a subcutaneous xenograft 4T1 murine tumor located on the left and right hind limbs.
  • An 808 nm laser was used as excitation (140 mW ⁇ cm -2 ) filtered through 850 nm short-pass filter.
  • Dynamic imaging was done with a 2D InGaAs camera (Princeton Instrument 2D-OMA V: 320) with exposure time of 300 ms in the > 1100 nm range (by collecting emission through 1, 100-nm long-pass filter) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/CN2016/081265 2016-05-06 2016-05-06 Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging WO2017190345A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2016/081265 WO2017190345A1 (en) 2016-05-06 2016-05-06 Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging
CN201680087445.5A CN109641921B (zh) 2016-05-06 2016-05-06 分子荧光团及其制备方法和用于短波红外成像的用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2016/081265 WO2017190345A1 (en) 2016-05-06 2016-05-06 Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging

Publications (1)

Publication Number Publication Date
WO2017190345A1 true WO2017190345A1 (en) 2017-11-09

Family

ID=60202677

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2016/081265 WO2017190345A1 (en) 2016-05-06 2016-05-06 Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging

Country Status (2)

Country Link
CN (1) CN109641921B (zh)
WO (1) WO2017190345A1 (zh)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019012514A1 (en) * 2017-07-14 2019-01-17 King Abdullah University Of Science And Technology ADJUSTABLE SIZE CONJUGATED POLYMER NANOPARTICLES HAVING FLUORESCENCE IN THE SPECTRAL DOMAIN BETWEEN FAR RED AND SHORT WAVELENGTH INFRARED
CN109369684A (zh) * 2018-11-01 2019-02-22 华东师范大学 一类电子供体-受体-供体荧光分子及其制备方法和应用
CN110237272A (zh) * 2019-06-25 2019-09-17 武汉大学苏州研究院 适用于mri/nir-ii的双模态肿瘤成像纳米探针、制备方法及应用
WO2019221386A1 (ko) * 2018-05-17 2019-11-21 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 전자 소자
WO2019218276A1 (en) * 2018-05-16 2019-11-21 Merck Patent Gmbh Organic semiconductors
WO2020015700A1 (en) * 2018-07-18 2020-01-23 The Hong Kong University Of Science And Technology Photothermal agents
EP3858839A1 (en) * 2020-01-30 2021-08-04 Samsung Electronics Co., Ltd. Infrared absorbers, infrared absorbing/blocking films, photoelectric devices, organic sensors, and electronic devices
CN114790215A (zh) * 2021-01-25 2022-07-26 中国科学院上海药物研究所 基于喹喔啉的d-a-d近红外二区荧光分子及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239025A1 (en) * 2019-05-28 2020-12-03 The Hong Kong University Of Science And Technology An ultrabright nir-ii aiegen for bioimaging
CN111840251B (zh) * 2020-06-30 2022-07-08 南方科技大学 靶向纳米颗粒及制备方法、应用、系统、设备及存储介质
CN112552490B (zh) * 2020-12-11 2023-04-14 南方科技大学 一种核酸接枝半导体聚合物、核酸探针及其制备方法和应用
CN114478587B (zh) * 2021-12-29 2023-07-28 南京邮电大学 一种近红外二区染料、纳米粒子及其制备方法和应用
CN114560874A (zh) * 2022-01-19 2022-05-31 南京邮电大学 一种阳离子型水溶性近红外二区荧光成像造影剂及其应用
CN114751918B (zh) * 2022-05-07 2023-04-11 深圳大学 新型近红外二区激发聚集诱导发光材料及制备方法、应用
CN115710283A (zh) * 2022-10-18 2023-02-24 郑州中科生物医学工程技术研究院 化合物及其制备方法和应用、近红外-IIa荧光成像造影剂的制备方法
CN116178454B (zh) * 2023-01-10 2024-09-20 南华大学 化合物IR-FE-Fc、IR-FE-Fc自组装纳米材料及制备方法和抗肿瘤应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014107606A2 (en) * 2013-01-04 2014-07-10 Nitto Denko Corporation Highly-fluorescent and photo-stable chromophores for wavelength conversion
WO2015012913A2 (en) * 2013-04-22 2015-01-29 Massachusetts Institute Of Technology Short-wavelength infrared (swir) fluorescence in vivo and intravital imaging with semiconductor nanocrystals
WO2015041026A1 (ja) * 2013-09-20 2015-03-26 宇部興産株式会社 ベンゾビス（チアジアゾール）誘導体、それを含むインク、およびそれを用いた有機エレクトロニクスデバイス
US20150295182A1 (en) * 2014-04-09 2015-10-15 Seiko Epson Corporation Light-emitting element, light emission apparatus, authentication apparatus, and electronic machine
WO2016112220A1 (en) * 2015-01-07 2016-07-14 Nitto Denko Corporation Highly photo-stable bis-triazole fluorophores

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014107606A2 (en) * 2013-01-04 2014-07-10 Nitto Denko Corporation Highly-fluorescent and photo-stable chromophores for wavelength conversion
WO2015012913A2 (en) * 2013-04-22 2015-01-29 Massachusetts Institute Of Technology Short-wavelength infrared (swir) fluorescence in vivo and intravital imaging with semiconductor nanocrystals
WO2015041026A1 (ja) * 2013-09-20 2015-03-26 宇部興産株式会社 ベンゾビス（チアジアゾール）誘導体、それを含むインク、およびそれを用いた有機エレクトロニクスデバイス
US20150295182A1 (en) * 2014-04-09 2015-10-15 Seiko Epson Corporation Light-emitting element, light emission apparatus, authentication apparatus, and electronic machine
WO2016112220A1 (en) * 2015-01-07 2016-07-14 Nitto Denko Corporation Highly photo-stable bis-triazole fluorophores

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANTARIS A.L. ET AL.: "A small-molecule dye for NIR-II imaging", NATURE MATERIALS, vol. 15, 29 February 2016 (2016-02-29), pages 235 - 243, XP055420687 *
FENG G.X. ET AL.: "Conjugated polymer microparticles for selective cancer cell image-guided photothermal therapy", JOURNAL OF MATERIALS CHEMISTRY B, vol. 3, 3 December 2014 (2014-12-03), pages 1135 - 1141, XP055435805 *
QIAN, G . ET AL.: "Band Gap Tunable, Donor-Acceptor-Donor Charge-Transfer Heteroquinoid-Based Chromophores: Near Infrared Photoluminescence and Electroluminescence", CHEM. MATER ., vol. 20, no. 19, 18 September 2008 (2008-09-18), pages 6208 - 6216, XP055435804 *
QIAN, G. ET AL.: "Design, synthesis, and properties of benzobisthiadiazole-based donor-pi- acceptor-Jt-donor type of low-band-gap chromophores and polymers", CHEM. MATER., vol. 88, 19 January 2010 (2010-01-19), pages 192 - 201, XP008177745 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11639896B2 (en) 2017-07-14 2023-05-02 King Abdullah University Of Science And Technology Size controllable conjugated polymer nanoparticles with fluorescence in the spectral range between far-red and short-wavelength infrared
WO2019012514A1 (en) * 2017-07-14 2019-01-17 King Abdullah University Of Science And Technology ADJUSTABLE SIZE CONJUGATED POLYMER NANOPARTICLES HAVING FLUORESCENCE IN THE SPECTRAL DOMAIN BETWEEN FAR RED AND SHORT WAVELENGTH INFRARED
WO2019218276A1 (en) * 2018-05-16 2019-11-21 Merck Patent Gmbh Organic semiconductors
WO2019218828A1 (en) * 2018-05-16 2019-11-21 Merck Patent Gmbh Organic semiconductors
US11401275B2 (en) 2018-05-17 2022-08-02 Lg Chem, Ltd. Non-fullerene based heterocyclic compound and organic electronic device including same
CN110730783A (zh) * 2018-05-17 2020-01-24 株式会社Lg化学 杂环化合物和包含其的有机电子器件
JP2020523288A (ja) * 2018-05-17 2020-08-06 エルジー・ケム・リミテッド ヘテロ環化合物およびこれを含む有機電子素子
WO2019221386A1 (ko) * 2018-05-17 2019-11-21 주식회사 엘지화학 헤테로환 화합물 및 이를 포함하는 유기 전자 소자
CN110730783B (zh) * 2018-05-17 2022-03-18 株式会社Lg化学 杂环化合物和包含其的有机电子器件
WO2020015700A1 (en) * 2018-07-18 2020-01-23 The Hong Kong University Of Science And Technology Photothermal agents
CN112566911A (zh) * 2018-07-18 2021-03-26 香港科技大学 光热试剂
CN112566911B (zh) * 2018-07-18 2023-09-01 香港科技大学 光热试剂
CN109369684A (zh) * 2018-11-01 2019-02-22 华东师范大学 一类电子供体-受体-供体荧光分子及其制备方法和应用
CN109369684B (zh) * 2018-11-01 2021-07-27 华东师范大学 一类电子供体-受体-供体荧光分子及制备方法和应用
CN110237272B (zh) * 2019-06-25 2022-02-15 武汉大学苏州研究院 适用于mri/nir-ii的双模态肿瘤成像纳米探针、制备方法及应用
CN110237272A (zh) * 2019-06-25 2019-09-17 武汉大学苏州研究院 适用于mri/nir-ii的双模态肿瘤成像纳米探针、制备方法及应用
EP3858839A1 (en) * 2020-01-30 2021-08-04 Samsung Electronics Co., Ltd. Infrared absorbers, infrared absorbing/blocking films, photoelectric devices, organic sensors, and electronic devices
US12120951B2 (en) 2020-01-30 2024-10-15 Samsung Electronics Co., Ltd. Infrared absorbers, infrared absorbing/blocking films and photoelectric devices and organic sensors and electronic devices
CN114790215A (zh) * 2021-01-25 2022-07-26 中国科学院上海药物研究所 基于喹喔啉的d-a-d近红外二区荧光分子及其制备方法和应用
CN114790215B (zh) * 2021-01-25 2023-10-31 中国科学院上海药物研究所 基于喹喔啉的d-a-d近红外二区荧光分子及其制备方法和应用

Also Published As

Publication number Publication date
CN109641921A (zh) 2019-04-16
CN109641921B (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
WO2017190345A1 (en) Molecular fluorophores and preparation method thereof and use for short wavelength infrared imaging
US10894121B2 (en) Small molecule dye for molecular imaging and photothermal therapy
Luo et al. A review of NIR dyes in cancer targeting and imaging
Peng et al. Soft fluorescent nanomaterials for biological and biomedical imaging
JP6606487B2 (ja) ｉｎｖｉｔｒｏおよびｉｎｖｉｖｏイメージングおよび検出のための置換シラキサンテニウム赤色〜近赤外蛍光色素
Shen et al. Recent development of small-molecule organic fluorophores for multifunctional bioimaging in the second near-infrared window
ES2670852T3 (es) Colorantes con policiclo y uso de los mismos
Sato et al. Role of fluorophore charge on the in vivo optical imaging properties of near-infrared cyanine dye/monoclonal antibody conjugates
US11549017B2 (en) NIR to SWIR fluorescent compounds for imaging and detection
JP5313249B2 (ja) ナノ粒子を用いた蛍光共鳴エネルギ移動検出
KR20200008596A (ko) 작용화된 나노 입자 및 이의 제조 및 사용방법
US20050169844A1 (en) Near infrared imaging agent
CN103402547B (zh) 开关型荧光纳米颗粒探针以及使用其的荧光分子成像法
CN101440282A (zh) 近红外荧光分子探针及其合成方法和用途
Cole et al. Water-soluble, deep-red fluorescent squaraine rotaxanes
Barat et al. Cys-diabody quantum dot conjugates (immunoQdots) for cancer marker detection
JP2016519080A (ja) ４，４−二置換シクロヘキシル架橋ヘプタメチンシアニン色素およびその使用
US20180134689A1 (en) Benzocyanine compounds
WO2018014865A1 (en) Aiegens for cancer cell imaging
CN114057773A (zh) 一种近红外二区聚集诱导发光分子及其应用
EP2683413A1 (en) In vivo selection of therapeutically active antibodies
US10493168B2 (en) Phosphorescent meso-unsubstituted metallo-porphyrin probe molecules for measuring oxygen and imaging methods
Gowtham et al. Nano-fluorophores as enhanced diagnostic tools to improve cellular imaging.
KR101334696B1 (ko) 광변색화합물로 가교된 덴드리머 나노클러스터 구조에 기반한 고대비 생체 이미징을 위한 가역성 형광 스위치
Swamy et al. Biocompatible and Water-Soluble Shortwave-Infrared (SWIR)-Emitting Cyanine-Based Fluorescent Probes for In Vivo Multiplexed Molecular Imaging

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16900867

Country of ref document: EP

Kind code of ref document: A1

122 Ep: pct application non-entry in european phase

Ref document number: 16900867

Country of ref document: EP

Kind code of ref document: A1